Antiviral clinical trial design throughout the COVID pandemic: evolving endpoints and lessons learnt
Future pandemics will almost certainly continue to arise. Similarly, the landscape will continue to evolve alongside our understanding of the disease. Designing trials that remain scientifically rigorous and practical while still addressing the changing natural history of the disease continues to pose a challenge.
Authors
- André C. Kalil (ORCID: https://orcid.org/0000-0002-6489-6294)
- Beatrice Sim (ORCID: https://orcid.org/0000-0003-1845-4476)
- Cameron R. Wolfe (ORCID: https://orcid.org/0000-0002-5365-5030)
Institutions
- The University of Melbourne (AU)
- Duke University (US)
- Peter MacCallum Cancer Centre (AU)
- Victorian Comprehensive Cancer Centre (AU)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Current Opinion in Infectious Diseases
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1097/qco.0000000000001165
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00